SCHEMBL13043660

SCHEMBL13043660

Cc1nc(N2CCOCC2)ccc1C(=O)Nc1ccc(Cl)c(-c2nccc3ccccc23)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.49
▸ KDM4E B2RXH2 3/20 0.48
▸ HIF1A Q16665 3/20 0.48
▸ ALDH1A1 P00352 2/20 0.47
▸ CNR1 P21554 1/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ PPARG P37231 2/20 0.46
▸ RAF1 P04049 3/20 0.45
▸ BRAF P15056 3/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ DGAT1 O75907 1/20 0.43
▸ MTOR P42345 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13552826 0.86 CYP2C9 (0.40) CNR1
SCHEMBL13552655 0.86 PKM (0.51) RAB9AALDH1A1CNR1CYP1A2PPARG
SCHEMBL13552812 0.85 MAPT (0.54) RAB9ACYP1A2PPARGRAF1BRAF
SCHEMBL13553142 0.83 CYP2C9 (0.46) —
SCHEMBL13552994 0.83 MTOR (0.53) RAB9AKDM4ECNR1PPARGRAF1
SCHEMBL13553013 0.82 PIK3CB (0.43) KDM4EALDH1A1MAPT
SCHEMBL13552999 0.82 CLK2 (0.51) RAB9AKDM4ECNR1PPARGBRAF
SCHEMBL13044272 0.81 KMT2A (0.50) RAB9AKDM4EALDH1A1CNR1MAPT
SCHEMBL13044296 0.80 RAB9A (0.49) RAB9ACYP1A2PPARGMAPTNPC1
SCHEMBL13043657 0.79 CYP2C9 (0.62) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
EP-2440048-B1 ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING CALIFORNIA CAPITAL EQUITY LLC (US) 2015-10-07 — — EP disclosed
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-25 — — US disclosed
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-25 — — US disclosed
WO-2010144586-A1 ISOQUINOLINE, QUINOLINE, AND QUINAZOLINE DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING ABRAXIS BIOSCIENCE, LLC (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling SHH, GLI1, SMO RAB9A 447/4885KDM4E 2061/4885HIF1A 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback